Year: 2026
Type: article
Study design: Case Report
Abstract: Introduction: Imatinib mesylate is first line therapy for chronic phase chronic myeloid leukemia (CML). Serositis is a rare, life-threatening, imatinib-induced complication, reported in 1.3% of newly diagnosed and 2% of other chronic phase CML patients, that may result in respiratory compromise or cardiac tamponade. Case Presentation: 72-year-old-male with CML in molecular remission on imatinib presented with recurrent pleural effusions and new pericardial effusions concerning for pre-tamponade physiology, suspected to be imatinib induced serositis. Imatinib was discontinued with resolution of effusions. The patient was transitioned to nilotinib with maintenance of BCR-ABL negativity and good tolerability. Conclusion: This case highlights the importance of recognizing imatinib-induced serositis. Prompt therapy modification can prevent morbidity while maintaining molecular remission.
Institution: Reading Hospital
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $500
OpenAlex ID: W7236337101
